key: cord-0982510-ylm5i8jc
authors: Egeli, Bugra Han; Sparks, Jeffrey A.; Kim, Alfred H.J.; Liew, Jean W.
title: Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?
date: 2021-01-01
journal: Best Pract Res Clin Rheumatol
DOI: 10.1016/j.berh.2020.101658
sha: 3c4fd4b87d07f708b361b8bca32989291f9f1122
doc_id: 982510
cord_uid: ylm5i8jc

A variety of treatment modalities have been investigated since the beginning of the Coronavirus Disease-19 (COVID-19) pandemic. The use of antimalarials (hydroxychloroquine and chloroquine) for COVID-19 treatment and prevention has proven to be a cautionary tale for widespread, off-label use of a medication during a crisis. The investigation of antimalarials for COVID-19 has also been a driver for a deluge of scientific output in a short amount of time. In this narrative review, we detail the evidence for and against antimalarial use in COVID-19, starting with the early small observational studies that influenced strategies worldwide. We then contrast these findings to later published larger observational studies and randomized controlled trials. We detail the emerging possible cardiovascular risks associated with antimalarial use in COVID-19, and whether COVID-19-related outcomes and cardiovascular risks may differ for antimalarials used in rheumatic diseases.

The Coronavirus Disease 2019 (COVID- 19) pandemic has disrupted all aspects of society. In the midst of a global health disaster, there has been a sprint to find safe and effective treatments. There was early in vitro evidence for antimalarial drugs such as hydroxychloroquine (HCQ) or chloroquine (CQ) for use against SARS-CoV-2, the virus that causes COVID-19 [1] [2] [3] .

As the pandemic spread around the world, so did the off-label use of antimalarials. This led to many retrospective and prospective observational studies and multiple randomized controlled trials (RCTs). With the dissemination of knowledge about HCQ in COVID-19 treatment, issues arose of scientific communication, research ethics, and the conduct of medical research. By the end of June 2020, the enthusiasm for HCQ in treating COVID-19 seemed to wane as evidence pointed towards its inefficacy for this indication. In this review, we examine the evidence for the efficacy of antimalarials for COVID-19 treatment and prevention, as well as the safety of antimalarial use in COVID-19. We then discuss the efficacy of antimalarials for COVID-19related outcomes in patients with rheumatic diseases, as well as the evidence for associated cardiovascular risks in this population.

The initial studies for the efficacy of antimalarials for the treatment of COVID-19 were small studies that were mostly performed in France and China [4] [5] [6] [7] . Most of these were not controlled and those that did often did not have adequate comparison groups. With time, larger observational studies were published [8, 9] . These overall did not show a beneficial effect on mortality or the need for mechanical ventilation in hospitalized patients with COVID-19. Later RCT data did not demonstrate efficacy among this population of patients who were hospitalized for COVID- 19 . In this section, we review the evidence for antimalarials for COVID-19 treatment in the general population using observational ( Table 1) and RCTs ( Table 2 ).

Smaller observational studies Huang, et al. reported the results of their multicenter prospective observational study from 12 hospitals in the Guangdong and Hubei Provinces [10] . A group of 197 patients was treated with CQ 500 mg daily for up to 10 days, whereas the comparator group of 176 patients did not receive any CQ treatment, per decision-making on the part of the clinician and patient (i.e., not randomized). The primary outcome was time to negative polymerase chain reaction (PCR) conversion and the secondary outcomes were the proportion of the patients with PCR conversion at days 10 and 14, hospital length of stay, duration of fever, and adverse events.

The time to undetectable viral PCR was significantly shorter in the CQ group as well as the duration of fever and the length of the hospital stay. There was also a significant difference in seroconversion at day 14 between the CQ group (96%) and the control (80%).

In the first single-center series from Marseilles, France the authors reported 42 inpatients who had received HCQ [11] . These were compared to patients who were treated at other hospitals in the same region, or patients who had contraindications to HCQ or had declined its use. The outcome was viral clearance at six days, which was seen in 70% of those on HCQ versus 13% of those receiving standard of care. However, this first study was complicated by many design flaws which have previously been discussed in prior publications [12, 13] . These design flaws include the lack of an adequate comparator group, the removal of those who had been lost to follow-up who had the primary outcome of death, and the use of a surrogate outcome of viral clearance rather than in outcomes such as death or worsening symptoms.

In the second study from the same group in Marseilles, 80 patients receiving HCQ and azithromycin (including six reported by the authors previously) were assessed for a favorable outcome, as defined by negative viral load, length of stay, and negative viral cultures [14] . The authors reported that 81% of participants in this case series had a favorable outcome.

In the third study from the same group, 1061 patients receiving HCQ 200 mg twice daily for ten days and azithromycin 500 mg on day one followed by 250 mg daily were investigated [15] . The outcomes of interest included death, worsening of disease (intensive care unit [ICU] transfer or length of stay greater than ten days), viral shedding that persisted for more than ten days. A poor outcome was based on a composite of these events and was seen in 46 (4.3%). Eight patients (0.75%) died in this study.

A Spanish single-center study of 166 patients presented results on a reduction in mortality associated with an initial HCQ loading dose of 800 mg [16] . There was a significant difference in mortality between the HCQ group (22%) and the comparator group (48.8%) (p=0.002).

However, the inclusion criteria of the study did not require PCR positivity, so patients were included if they had a probable clinical picture and the presence of bilateral interstitial pneumonia on imaging. The duration of the symptoms prior to admission was reported in the HCQ group, but not in the non-HCQ group, which may be an important confounding factor.

These two points hinder the interpretation of the results of the study. A small retrospective study from the UAE showed an association of HCQ with longer time to negative PCR conversion in 34 hospitalized patients when compared to no HCQ use [17] .

Seemingly counter to this evidence, a small French case series of 11 patients with the primary outcome of viral load at six days demonstrated negative results [18] . These authors found that there was a persistent viral load in eight out of ten patients who had received HCQ. This series was followed by the publication of a larger observational study by Mahevas, et al [19] . This study included a total of 181 patients from four French sites who required supplemental oxygen for COVID-19 that were included in these analyses. HCQ was given within 48 hours of admission in the main analysis. The primary outcome of interest was survival without ICU J o u r n a l P r e -p r o o f transfer within 21 days. This study did not find a significant association between use of HCQ versus no HCQ on this primary outcome. Secondary outcomes of interest included overall survival, survival without acute respiratory distress syndrome, ability to wean supplemental oxygen, and discharge from the hospital. There were no significant associations with HCQ use in any of these secondary outcomes.

Finally, in a retrospective study from a single center in China, 284 hospitalized patients were assessed for outcomes of viral clearance and length of stay [20] . Overall, 65% of patients were on supplemental oxygen, 8.5% required an ICU level of care, and 1.4% required mechanical ventilation. Twenty-five patients received CQ. The authors assessed the association of antiviral therapy and the outcome of clearance at 14 days. Therapies assessed included CQ, lopinavir/ritonavir, and oseltamivir. Overall 89% had viral clearance by 21 days, and this was not significantly shortened by any antiviral therapy including CQ.

These small studies were followed by the publication of larger observational studies. Some of these studies leveraged electronic health records as data sources, providing higher power to evaluate relatively rare outcomes among a large sample of individuals. However, this comes with the tradeoff of being less able to ascertain important confounding or outcome variables.

One of the larger retrospective studies from China included 568 patients at a critical condition with acute respiratory distress syndrome (ARDS) [21] . Of these patients, 48 were treated with HCQ at a dose of 200 mg twice a day for 7-10 days. The authors found a lower mortality rate in the group that received HCQ compared to the patients who did not (18.8% to 45.8%, p<0.001).

Interleukin-6 level was a secondary outcome of the study, which was significantly lower in the HCQ group at the end of the treatment.

In a random sample of patients admitted for COVID-19 in the New York Metropolitan area, Rosenberg, et al. found no association between the use of HCQ with or without azithromycin on the outcome of in-hospital mortality [8] . Geleris, et al. investigated the impact of HCQ treatment on the outcomes of intubation or death using observational data from 1446 hospitalized patients with COVID-19 in New York City [9] . Their study also found no significant association with the primary outcome. Methodologically, the authors accounted for confounding by indication using inverse probability weighting. Although doing so does not reproduce the results of an RCT, using these methods, one can better approximate the causal effects of treatment, given a set of certain assumptions. These assumptions include a well-designed study, having appropriate and well-measured data, and correctly identifying potential confounders.

The study by Magagnoli, et al. used national US data from the Veterans Health Administration to assess the risk of death comparing those treated with HCQ versus not, or HCQ with azithromycin versus neither, among patients admitted for COVID-19 [22] . Although they found a nonsignificant association of HCQ and azithromycin treatment and the outcome of death, there was a statistically higher risk of death for those on HCQ alone versus standard of care. There was no association for the secondary outcome of mechanical ventilation for both those receiving HCQ alone and those receiving HCQ with azithromycin. The interpretation of these results is difficult. The combination of HCQ and azithromycin may have been expected to have similar or even worse outcomes as was observed in HCQ monotherapy vs. standard of care given possible interaction for QTc prolongation. Enhanced efficacy of combination therapy for COVID-19 could possibly have dampened the excess mortality of HCQ monotherapy. However, it is most likely that these results may have been biased due to the threats of study validity, particularly unmeasured and residual confounding. 19 disease severity, there remains a concern that their results of a protective association may be due to residual and unmeasured confounding, particularly the concomitant use of steroids that appear to be effective in severe COVID-19 [24] . Also, there may be strong temporal trends over calendar time for HCQ use during the early period of the pandemic. These issues limit the inference that can be drawn from these results.

By June 2020, the data from large, well-designed observational studies and emerging evidence from RCTs pointed towards a lack of efficacy for antimalarials in the treatment of COVID-19.

The systematic review and meta-analysis by Putman, et al. reported data from 45 studies up until May 2020, which included hospitalized COVID-19 patients who were treated with medications commonly used as antirheumatic therapies medication [25] . When pooled, the three included cohort studies assessing HCQ did not demonstrate an association with COVID-19 mortality. A later systematic review and meta-analysis by Fiolet, et al. included 29 studies until the end of July 2020 [26] . This review only included studies with the primary outcome of mortality. The results of the study were in agreement with the earlier meta-analysis, with no benefit seen for HCQ on COVID-19 mortality.

In the early stages of the pandemic, multiple small RCTs were initiated to study the effect of HCQ on COVID-19-related outcomes ( Table 2) . These trials were later followed by larger, multinational RCTs, though many of these were terminated early due to inefficacy of the intervention under study.

Chen, et al. conducted a single center RCT in Wuhan [5] with 62 participants randomized to HCQ 400 mg daily for four days compared to standard of care. The primary outcome was recovery (return to normal body temperature for 72 hours or the resolution of cough 72 hours).

Both outcomes were significantly reduced in the intervention group compared to controls. In another small trial conducted by Huang, et al., 22 hospitalized patients were randomized into two groups based on the treatment modality: CQ 500 mg twice daily for ten days compared to standard of care [7] . The primary outcome was seroconversion at 10 days which was not found statistically significant. An open-label study conducted in China of 48 patients with moderate severity COVID-19 randomized patients to CQ (dosed 1000mg for one day, then 500mg daily for nine days), HCQ (200mg twice daily for ten days), or control, with a primary outcome of time to clinical recovery and a secondary outcome of viral RNA seroconversion [27] . Both were significantly shorter in the CQ group and the HCQ group had quicker seroconversion compared to controls.

In a larger open-label controlled trial comprising 16 centers in China that enrolled 150 patients, the findings were negative [28] . Participants were randomized to HCQ 1200 mg for three days and subsequently 800 mg daily versus standard of care, assessing the outcome of seroconversion at 28 days.

Chlorocovid was a phase IIb randomized control trial comparing two doses of CQ among patients in Brazil hospitalized with COVID-19 compared to historical controls from Wuhan [29] .

In this study, there was a possible safety signal of QTC prolongation seen for CQ, but no clinical benefit was detected. High dose CQ at 600 mg twice daily for ten days was associated with higher risk of mortality versus low dose of CQ at 450 mg twice a day for one day followed by 450 mg daily for four days.

Several large, multinational RCTs were stopped in late May/early June 2020 due to inefficacy, including the HCQ arm of RECOVERY (Randomised Evaluation of COVID-19 Therapy), the WHO-sponsored Solidarity, and the NIH-sponsored ORCHID (Outcomes Related to COVID-19

Treated with HCQ Among Patients with Symptomatic Disease). The HCQ arm of the RECOVERY trial was reported in mid-July [30] . 1561 participants hospitalized with COVID-19 from the UK were randomized to HCQ (800mg followed by 800mg six hours later, and subsequently 400mg twice daily for nine days) versus usual care. The primary outcome of this well-powered study was mortality at 28 days, which was not significantly different between the two groups (rate ratio [RR] 1.09, 95% CI 0.96-1.23). Subgroup analyses, including by age, sex, level of respiratory support, and days since symptom onset, did not show meaningful differences in the primary outcome in any subgroup. Two of the secondary outcomes actually favored usual care -the HCQ intervention group had a significantly longer length of stay and were more likely to progress to mechanical ventilator or death. This was the first large-scale RCT reported for HCQ in hospitalized patients with COVID-19, although it did not provide data on those with early or less severe infection.

Two other RCTs were reported in mid-July 2020, both evaluating the use of HCQ in non- symptom onset less than five days and who were not hospitalized [32] . The dosing of HCQ was 800mg followed by 400mg daily for six days. The primary outcome of reduction in RNA viral load at seven days after treatment initiation was not statistically significant comparing the two groups, nor were the secondary outcomes of disease progression or time to symptom resolution. Limitations of this study included its lack of a placebo and the use of a surrogate outcome.

A Brazilian placebo-controlled RCT by Cavalcanti, et al. has further disproven the efficacy of HCQ, either alone or with azithromycin in mild-to-moderate hospitalized COVID-19 patients [34] .

Patients were randomized and equally distributed to either receive standard treatment, an additional 400 mg twice daily HCQ to the standard treatment, or standard care with the same HCQ regimen as the prior group plus daily azithromycin at a dose of 500 mg. Neither of the treatment groups had a statistically significant benefit over the negative control group in terms of the primary and the secondary outcomes. Furthermore, HCQ treatment was associated with a higher frequency of adverse events, such as elevation of liver enzymes, and QTc interval prolongation.

Boulware, et al. conducted a multicenter RCT at sites in the US and Canada [33] . They randomized 821 participants who were asymptomatic but had had household or occupational exposure to a confirmed COVID-19 case. Overall, 66.4% were healthcare workers; the median age was 40 years, and 27.4% with at least one chronic condition. Participants were further stratified by high risk (<6 feet, >10-minute contact without facemask or eye shield) and moderate risk (<6 feet, >10-minute contact with face mask but no eye shield). They were randomized to HCQ 800mg once, then 600mg in 6-8 hours, then 600mg daily for 4 days, versus placebo. The primary outcome was laboratory confirmed COVID-19 or COVID-19-like illness within 14 days assessed by follow-up surveys online or by phone. The outcome occurred in 11.8% in the HCQ group vs 14.3% in the placebo group and was not statistically different. The secondary outcomes, COVID-19 hospitalization or death, were also not statistically significant.

Side effects more common with HCQ than placebo (40.1% vs 16.8%). Limitations of this study included the following: the inclusion of a younger, healthier population rather than a more at-risk population; and limited access to confirmatory testing of COVID-19, especially for participants in the US.

An open-label, cluster-randomized trial conducted in Catalonia, Spain also assessed the use of HCQ as a post-exposure prevention [35] . The intervention arm (n=1116) was treated with 800mg once, then 400 mg daily for six days, while the control group (n=1198) received no specific treatment. The primary outcome of confirmed COVID-19 infection within 14 days was not statistically significant (6.2% control group vs. 5.7% HCQ, RR 0.89, 95% CI 0.54-1.46).

Adverse event frequency was higher in the treatment arm (51.6% vs. 5.9%) (p<0.001) mostly consisting of mild gastrointestinal symptoms, but cardiac side effects consisting of palpitations were only seen in 0.4% of the treatment arm (vs. 0.1% in the control arm).

The importance of these last several RCTs [31] [32] [33] [34] [35] were that they were published at a time when the RCTs of hospitalized COVID-19 patients were criticized for assessing the efficacy of HCQ in a subset of patients who had higher disease severity. The RCTs in early, nonhospitalized COVID-19, and the multiple RCTs in hospitalized COVID-19 have emphasized the lack of efficacy of HCQ in COVID-19.

In April 2020, hypotheses that patients with systemic lupus erythematosus (SLE) were protected against COVID-19, possibly through their use of HCQ, began to spread. Initial case series of SLE patients were mixed, with some including patients with severe diseases [36] and others including only patients with mild or moderate courses [37] . Ramirez, et al. systematically reviewed SLE-and COVID-19 related publications through the end of June 2020, concluding that the data did not support a protective association between HCQ and COVID-19 among subjects with SLE [38] .

The COVID-19 Global Rheumatology Alliance registry published an analysis with 600 patients with COVID-19 disease from 40 countries with rheumatic conditions including rheumatoid arthritis (RA) (38%), SLE (14%), and psoriatic arthritis (12%) [39, 40] . Among these, 22% were on antimalarials prior to COVID-19 diagnosis. The use of antimalarials was not significantly associated with hospitalization following COVID-19 diagnosis. This study was limited by the method of data collection (i.e., voluntary entry by physicians into an online registry), and there was potential selection bias towards more severe cases. admission and mechanical ventilation, which was higher in the rheumatic disease group (48% to 18%) (p=0.01). The admission and mortality rates were similar in both groups. In the group of patients with rheumatic disease, there was no significant difference between hospitalized and non-hospitalized patients regarding the use of antimalarial therapy. This study was not powered to evaluate the association of antimalarial use and any of these outcomes.

The evidence for possible cardiovascular toxicity with antimalarial treatment in COVID-19 has come from small studies from the US and Europe. These data are presented in Table 3 .

Four observational studies from the US evaluated the cardiovascular safety of antimalarial treatment with or without concomitant azithromycin [42] [43] [44] [45] . One study was prospective and the others were retrospective. All compared the post-antimalarial treatment QTc interval with the baseline. Mercuro, et al. reported that of the 90 who received HCQ, 19% had prolonged QTc [42] . Of the 53 who received HCQ and concomitant azithromycin, this frequency was 21%. A later-retracted large observational study using purported international registry data on nearly 100,000 patients with COVID-19 found an increased risk of mortality and new arrhythmias for HCQ or CQ alone, and either antimalarial in combination with a macrolide, versus comparators receiving neither an antimalarial nor a macrolide [49, 50] . The issues with the integrity of the data source have been discussed at length [51] .

Although both CQ and HCQ are known to have potentially serious cardiovascular side effects, the data and clinical experience so far demonstrate their general tolerability as treatment for COVID-19 in the general population. These treatment modalities have been mostly analyzed using QTc prolongation as a surrogate outcome. Despite the primary mechanism of drug-J o u r n a l P r e -p r o o f induced arrhythmogenicity being QTc prolongation, fatal arrhythmias can also occur in patients with normal QTc interval [52] .

The studies described above demonstrate a potentially clinically relevant prolongation of the QTc interval (>500 ms) in at least 10% of the patients. The addition of azithromycin to antimalarial treatment was found to be associated with a longer QTc duration. However, the majority of the studies reached a conclusion that cardiovascular side effects rarely warrant the discontinuation of the treatment as there were no incidents of ventricular arrhythmia or torsades de pointes. Overall, these studies in COVID-19 were limited by small sample sizes and surrogate outcomes.

The concerns about cardiovascular safety with the use of antimalarials for COVID-19 led to a renewed interest in the same toxicity concerns among long-term users with rheumatic disease such as SLE or RA. Due to the need for large numbers to investigate rare outcomes, this question was primarily studied using administrative databases.

Lane, et al used claims data from 14 sources and spanning six countries in three continents to study HCQ with or without azithromycin versus active comparators (sulfasalazine and amoxicillin, respectively) [53] . They performed two separate studies: one in patients with RA using an active comparator design and one in the general population using a self-controlled case series design. Although their study did not find a difference in short-term outcomes with 30-day follow-up, they did detect a concerning safety signal: that HCQ combined with azithromycin was associated with increased risk of three separate outcomes: cardiovascular death, chest/pain angina, and heart failure.

Hooks, et al. performed an analysis of veterans in the Minneapolis Veterans Affairs system who were prescribed HCQ from the years 2000 to 2020 [54] . The majority of these patients had underlying SLE as the indication for treatment with HCQ. They evaluated characteristics associated with prolonged QTc intervals. However, comparing those with prolonged QTc intervals greater than or equal to 470 ms to those with normal QTc intervals, they did not find a statistically significant association with mortality. These data suggest that HCQ use, while associated with elevated QTc intervals in patients with SLE, were not associated with increased mortality in such patients. The studies from larger databases came to a conclusion that the use of HCQ as maintenance therapy in rheumatic diseases appeared to be safe with regards to cardiovascular safety. The combination treatment of HCQ with azithromycin is concerning and may require additional monitoring.

The rapid uptake of antimalarials for the treatment of COVID-19 has prompted both a fervor to publish, and a flurry of criticism. By September 2020, the data from large RCTs and well- intensive care unit; PCR: polymerase chain reaction; ARDS: acute respiratory distress syndrome **The definition of clinical recovery in this study is the resolution of fever and cough that is maintained for at least 72 hours.

J o u r n a l P r e -p r o o f 

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Treating COVID-19 with chloroquine

Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State

Observational study of hydroxychloroquine in hospitalized patients with Covid-19

Preliminary evidence from a J o u r n a l P r e -p r o o f multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial

A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19

Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: What every clinician should know

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: An observational study

Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial

Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19

Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19

United States veterans hospitalized with Covid-19. MedRxiv 2020

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Metaanalysis

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective openlabel randomized controlled study

Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial

Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis

Systemic lupus erythematosus and COVID-19: what we know so far

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin

Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection

Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring

Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit

Arrhythmic profile J o u r n a l P r e -p r o o f and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin

Chloroquine-induced QTc prolongation in COVID-19 patients

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19

The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review

Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study

Effects of hydroxychloroquine treatment on QT interval

Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist